Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol

Journal of Psychopharmacology

Volumn 24, Issue 1, 2010, Pages 73-82

  Liem Moolenaar, M ^a   Gray, F A ^b   De Visser, S J ^a   Franson, K L ^a   Schoemaker, R C ^a   Schmitt, J A J ^c   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Haloperidol; Healthy volunteers; NK3 antagonist; Pharmacology; Schizophrenia; Talnetant

Indexed keywords

HALOPERIDOL; HORMONE; PLACEBO; PROLACTIN; PSYCHEDELIC AGENT; TALNETANT;

ADAPTIVE BEHAVIOR; ADULT; AGED; ALERTNESS; ARTICLE; BODY EQUILIBRIUM; BRAIN; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; ELECTROENCEPHALOGRAM; FATIGUE; FEMALE; HUMAN; LEARNING; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SACCADIC EYE MOVEMENT; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH PURSUIT EYE MOVEMENT; SOMNOLENCE; TASK PERFORMANCE; THINKING; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; QUINOLINES; RECEPTORS, NEUROKININ-3; YOUNG ADULT;

EID: 76249129925     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108094524     Document Type: Article

References (44)

1. Beuzen, JN, Taylor, N., Wesnes, K., Wood, A. (1999) A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol 13: 152-158.
2. Bond, A., Lader, M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
3. Borland, RG, Nicholson, AN (1984) Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol 18 (Suppl. 1). S69 - S72.
4. Bowdle, TA, Radant, AD, Cowley, DS, Kharasch, ED, Strassman, RJ, Roy-Byrne, PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88.
5. Chavanon, ML, Wacker, J., Leue, A., Stemmler, G. (2007) Evidence for a dopaminergic link between working memory and agentic extra-version: an analysis of load-related changes in EEG alpha 1 activity. Biol Psychol 74: 46-59.
6. Cohen, AF, Ashby, L., Crowley, D., Land, G., Peck, AW, Miller, AA (1985) Lamotrigine (Bw430C). a potential anticonvulsant - effects on the central nervous-system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 20: 619-629.
7. Cuesta, MJ, Peralta, V., Zarzuela, A. (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17-28.
8. Dawson, LA, Cato, KJ, Scott, C., Watson, JM, Wood, MD, Foxton, R., et al. (2008) In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant). potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 33: 1642-1652.
9. de Haas, SL, de Visser, SJ, van der Post, JP, de Smet, M., Schoemaker, RC, Rijnbeek, B., et al. (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21: 374-383.
10. de Visser, SJ, van der Post, JP, de Waal, PP, Cornet, F., Cohen, AF, van Gerven, JM (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55: 39-50.
11. de Visser, SJ van der, PJ, Pieters, MS, Cohen, AF, van Gerven JM (2001 a) Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 51: 119-132.
12. de Visser, SJ, van Gerven, JM, Schoemaker, RC, Cohen, AF (2001 b) Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. Br J Clin Pharmacol 51: 423-428.
13. Dumont, GJ, de Visser, SJ, Cohen, AF, van Gerven, JM (2005) Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 59: 495-510.
14. Gijsman, HJ, van Gerven, JM, Verkes, RJ, Schoemaker, RC, Pieters, MS, Pennings, EJ, et al. (2002) Saccadic peak velocity and EEG as endpoints for a serotonergic challenge test. Hum Psychopharmacol 17: 83-89.
15. Harrison, PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
16. Kamali, F. (2001) Osanetant sanofi-synthelabo. Curr Opin Investig Drugs 2: 950-956.
17. Kemme, MJ vd Post, JP, Schoemaker, RC, Straub, M., Cohen, AF, van Gerven, JM (2003) Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 55: 518-525.
18. King, DJ (1994) Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand 380 (Suppl.). 53-58.
19. King, DJ (1997) Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP consensus group. J Psychopharmacol 11: 201-209.
20. Laeng, B., Lag, T., Brennen, T. (2005) Reduced stroop interference for opponent colors may be due to input factors: evidence from individual differences and a neural network simulation. J Exp Psychol Hum Percept Perform 31: 438-452.
21. Langlois, X., Wintmolders, C., te Riele, P., Leysen, JE, Jurzak, M. (2001) Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40: 242-253.
22. Legangneux, E., McEwen, J., Wesnes, KA, Bergougnan, L., Miget, N., Canal, M., et al. (2000) The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol 14: 164-171.
23. McCue, RE, Waheed, R., Urcuyo, L., Orendain, G., Joseph, MD, Charles, R., et al. (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 189: 433-440.
24. Meltzer, HY, Arvanitis, L., Bauer, D., Rein, W. (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984.
25. Norris, H. (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
26. Pretorius, JL, Phillips, M., Langley, RW, Szabadi, E., Bradshaw, CM (2001) Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol 52: 322-326.
27. Rey, A. (1964) L̈examen Clinique en Psychologie. Paris: Presses Universitaires de France.
28. Saletu, B., Grunberger, J., Linzmayer, L., Anderer, P. (1987) Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-Eeg and psychometry. Pharmacopsychiatry 20: 12-27.
29. Schmitt, JAJ, Jorissen, BL, Sobczak, S., van Boxtel, MPJ, Hogervorst, E., Deutz, NEP, et al. (2000) Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol 14: 21-29.
30. Severini, C., Improta, G., Falconieri-Erspamer, G., Salvadori, S., Erspamer, V. (2002) The tachykinin peptide family. Pharmacol Rev 54: 285-322.
31. Shughrue, PJ, Lane, MV, Merchenthaler, I. (1996) In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol 372: 395-414.
32. Sobczak, S., Honig, A., Nicolson, NA, Riedel, WJ (2002) Effects of acute tryptophan depletion on mood and cortisol release in first-degree relatives of type I and type II bipolar patients and healthy matched controls. Neuropsychopharmacology 27: 834-842. (Pubitemid 35335899)
33. Spooren, W., Riemer, C., Meltzer, H. (2005) Opinion: NK3 receptor antagonists: the next generation of antipsychotics. Nat Rev Drug Discov 4: 967-975.
34. Stoessl, AJ (1994) Localization of striatal and nigral tachykinin receptors in the rat. Brain Res 646: 13-18.
35. Stroop, JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-662.
36. Tooney, PA, Au, GG, Chahl, LA (2000) Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci Lett 283: 185-188.
37. van der Post, JP, de Visser, SJ, Schoemaker, RC, Cohen, AF, van Gerven, JM (2004) Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol 18: 221-227.
38. van Steveninck, AL (1993) Methods of assessment of central nervous system effects of drugs in man. Leiden: State University Leiden.
39. van Steveninck, AL (1994) Methods of assessment of central nervous system effects of drugs in man. Leiden: State University Leiden.
40. van Steveninck, AL, Gieschke, R., Schoemaker, RC, Roncari, G., Tuk, B., Pieters, MS, et al. (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41: 565-573.
41. van Steveninck, AL, Schoemaker, HC, Pieters, MS, Kroon, R., Breimer, DD, Cohen, AF (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 50: 172-180.
42. van Steveninck, AL, van Berckel, BN, Schoemaker, RC, Breimer, DD, van Gerven, JM, Cohen, AF (1999) The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 13: 10-17.
43. Wright, BM (1971) Simple mechanical ataxia-meter. J Physiol 218: 27P - 28P.
44. Yeudall, LT, Reddon, JR, Gill, DM, Stefanyk, WO (1987) Normative data for the Halstead-Reitan neuropsychological tests stratified by age and sex. J Clin Psychol 43: 346-367.